Harry Fisher – Project Manager – Benchmark’s prices and data empowers clients: from critical mineral contracts to EV battery supply chain investments and government policy.
Copyright 2023 – Finance News Network
28 Aug 2019 - Ingenia Communities Group Limited (ASX:INA) CFO, Scott Noble discusses the company's FY19 results, its portfolio and the demand for seniors' accommodation.
17 Feb 2023 - Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari discusses the company's upcoming plans to list on the NASDAQ and provides an update on the its clinical trials.
01 Aug 2023 - QX Resources Limited (ASX:QXR) Managing Director Steve Promnitz discusses progress with the company's lithium project in California, including permitting, access to water and timeline ahead.
12 Oct 2022 - icetana (ASX:ICE) CEO and Managing Director Matt Macfarlane discusses revenue growth, the company's strategic placement to Macnica, changes to the share registry and the outlook ahead.
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
06 Nov 2024 - Paul Sanger interviewed Damian Spring, CEO of Santana Minerals Limited (ASX:SMI), to discuss the Bendigo gold project, which has recently been designated as a fast-track project.
28 Feb 2024 - Chris Stevens - Chief Executive Officer & Executive Director - Coda Minerals (ASX:COD) is an advanced exploration company primed to unlock the value of the highly prospective Elizabeth Creek Copper Cobalt Project in South Australia’s world class mining jurisdiction, the Gawler Craton.
04 Dec 2019 - Xref Limited (ASX:XF1) CEO & Co-Founder, Lee-Martin Seymour, talks about the company's candidate reference checking solution for HR departments, partner integration and expansion.
15 Jul 2020 - Recce Pharmaceuticals Limited (ASX:RCE) Executive Director James Graham provides an update on positive data against a range of persistent bacteria using the company's synthetic antibiotic RECCE 327, commencement of Phase I human clinical trial in 2H20 and key priorities.